Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Surrogate end points].

M Bobbio

    Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology
    |August 10, 2000
    PubMed
    Summary
    This summary is machine-generated.

    Clinicians must differentiate between surrogate and true clinical end points. A reduction in surrogate markers like cholesterol does not always translate to improved patient survival or reduced disease incidence.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Practising Less is More: An Exploration of What it Means to See "This Patient" Not a "Patient Like This".

    Journal of bioethical inquiry·2024
    Same author

    Why are Cochrane hepato-biliary reviews undervalued by physicians as an aid for clinical decision-making?

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2009
    Same author

    [Professional driving and safety, a target for occupational medicine].

    La Medicina del lavoro·2007
    Same author

    The Myocardial Performance Index detects chronic cardiac allograft dysfunction sooner than other methods.

    The Journal of cardiovascular surgery·2006
    Same author

    Binding by serum IgA antibodies from patients with coeliac disease to monkey heart tissue.

    Scandinavian journal of gastroenterology·2004
    Same author

    [Methodologic rigour and ethics: from the patient to science].

    Cardiologia (Rome, Italy)·2002
    Same journal

    [In memoriam: Mauro Bertella (La Spezia, 07/14/1946-Vimercate, 05/17/2003)].

    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2009
    Same journal

    [Electrocardiographic artifacts due to the incorrect use of filters].

    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2009
    Same journal

    [An unusual cause of cardiac arrest].

    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2009
    Same journal

    [Interhospital transportation for primary angioplasty in acute myocardial infarction: not just a simple taxi ride!].

    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2009
    Same journal

    [The "Valle Belbo Project" for the prevention of ischemic heart disease: study design and correlations between alcohol and cardiovascular risk factors].

    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2009
    Same journal

    [The RUTA project (Registro UTIC Triveneto ANMCO). An e-network for the coronary care units for acute myocardial infarction].

    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2009
    See all related articles

    Area of Science:

    • Clinical trials and evidence-based medicine.
    • Biostatistics and epidemiological research.
    • Cardiovascular disease research and treatment efficacy.

    Background:

    • Surrogate end points, such as reduced cholesterol or blood pressure, are often used to evaluate treatment efficacy.
    • These markers are assumed to correlate with true end points like mortality or myocardial infarction.
    • However, their direct relationship with patient outcomes requires careful validation.

    Discussion:

    • The use of surrogate end points in clinical trials can be misleading.
    • Examples from cardiology trials (e.g., clofibrate, milrinone, flecainide, doxazosin) show that improving a surrogate does not guarantee reduced mortality.
    • This highlights the critical need for caution when interpreting surrogate end point data.

    Key Insights:

    Related Experiment Videos

    • Surrogate end points are indirect measures of treatment effectiveness.
    • True end points, such as mortality reduction, provide definitive evidence of patient benefit.
    • Clinical decisions should prioritize treatments validated by true end points.

    Outlook:

    • Future research should focus on validating surrogate end points against hard clinical outcomes.
    • Clinicians must critically assess the evidence supporting treatments based on surrogate markers.
    • Promoting evidence-based medicine ensures patient safety and optimal therapeutic strategies.